Compare Main Street Capital Corporation (MAIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Merck & Co., Inc. — how do they compare? Main Street Capital Corporation trades at $54.6 (market cap $5.08B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 60.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.02%). Which is the better fit depends on your goals.
| MAIN | MRK | |
|---|---|---|
Market Cap | $5.08B | $307.25B |
Sector | Financials | Health |
52-Week High | $67.54 | $129.52 |
52-Week Low | $49.63 | $77.60 |
Dividend Yield | 8.02% | 2.73% |
Enterprise Value | — | $350.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
